- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07940413
Bronchial Artery Embolization and Bronchoscopy in The Management of Hemoptysis in Cavitary Tuberculosis Lung Lesions
Efficacy of Bronchial Artery Embolization and Bronchoscopy in The Management of Hemoptysis in Cavitary Tuberculosis Lung Lesions
This study aimed to evaluate the efficacy and safety of combining Bronchial artery embolization with bronchoscopy in the management of hemoptysis in patients with cavitary pulmonary tuberculosis.
Studieoversikt
Status
Detaljert beskrivelse
The lungs have a dual arterial supply composed of the pulmonary and bronchial arterial systems. The pulmonary arteries account for 99% of the arterial supply and are responsible for gaseous exchange.
Combining bronchoscopy with Bronchial artery embolization may improve treatment outcomes and reduce recurrence rates. Despite the increasing use of Bronchial artery embolization, limited studies have evaluated the combined role of bronchoscopy and Bronchial artery embolization specifically in patients with cavitary pulmonary tuberculosis.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Mohamad B Abd-Elhafiz, MBBCH
- Telefonnummer: 00201140466319
- E-post: mohamedbahget1990@gmail.com
Studiesteder
-
-
-
Asyut, Egypt, 71511
- Rekruttering
- Al-Azhar University (Assiut)
-
Ta kontakt med:
- Mohamad B Abd-Elhafiz, MBBCH
- Telefonnummer: 00201140466319
- E-post: mohamedbahget1990@gmail.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age > 18 years.
- Confirmed pulmonary tuberculosis.
- Presence of cavitary lung lesions on computed tomography (CT) chest.
- Moderate or massive hemoptysis requiring intervention.
- Written informed consent.
Exclusion Criteria:
- Coagulopathy not corrected before intervention .
- Severe cardiac instability.
- Pregnancy.
- Pulmonary malignancy.
- Refusal to participate.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Group A
Patients will undergo bronchial artery embolization alone. |
Patients will undergo bronchial artery embolization alone. |
|
Eksperimentell: Group B
Patients will undergo bronchial artery embolization combined with bronchoscopy. |
Patients will undergo bronchial artery embolization combined with bronchoscopy. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of Participants Achieving Successful Control of Hemoptysis
Tidsramme: 24 hours after completion of the assigned intervention
|
Percentage of participants achieving complete cessation of hemoptysis without requiring an additional intervention to control bleeding will be recorded. |
24 hours after completion of the assigned intervention
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of Participants With Recurrent Hemoptysis
Tidsramme: 24 hours after completion of the assigned intervention
|
Percentage of participants experiencing a new episode of hemoptysis after initial successful bleeding control will be recorded. |
24 hours after completion of the assigned intervention
|
|
All-Cause Mortality
Tidsramme: 24 hours after completion of the assigned intervention
|
Percentage of participants who die from any cause during the specified follow-up period will be recorded. |
24 hours after completion of the assigned intervention
|
|
Need for repeat embolization
Tidsramme: 24 hours after completion of the assigned intervention
|
Percentage of participants requiring an additional bronchial artery embolization procedure because of persistent or recurrent hemoptysis will be recorded. |
24 hours after completion of the assigned intervention
|
|
Incidence of procedure-related complications
Tidsramme: 24 hours after completion of the assigned intervention
|
Incidence of procedure-related complications will be recorded. |
24 hours after completion of the assigned intervention
|
|
Length of hospital stay
Tidsramme: Till discharge from the hospital (Up to two weeks)
|
Length of hospital stay will be recorded from the admission till discharge from the hospital |
Till discharge from the hospital (Up to two weeks)
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Patologiske prosesser
- Sykdommer i luftveiene
- Blødning
- Lungesykdommer
- Tegn og symptomer, luftveier
- Patologiske tilstander, tegn og symptomer
- Tegn og symptomer
- Hemoptyse
- Diagnostiske teknikker og prosedyrer
- Diagnose
- Kirurgiske prosedyrer, operativ
- Minimalt invasive kirurgiske inngrep
- Diagnostiske teknikker, kirurgisk
- Endoskopi
- Diagnostiske teknikker, luftveissystem
- Thorax kirurgiske inngrep
- Lungekirurgiske prosedyrer
- Bronkoskopi
Andre studie-ID-numre
- AZFM-IRB/M-1000/2026/09/012
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
IPD-delingstidsramme
After the end of study for one year.
Tilgangskriterier for IPD-deling
The data will be available upon a reasonable request from the corresponding author.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .